Hormone-Refractory Prostate Cancer

Cleveland BioLabs has concluded a Phase II clinical trial for Curaxin CBLC102 in patients with Androgen-Independent (Hormone-Refractory) Prostate Cancer.

For more information, please refer to the Company’s published press release “Cleveland BioLabs Reports Advances in Curaxin Anticancer Program”, dated December 29, 2008, which may be found in the investor information section of this website under press releases.